Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E15.59 EPS (ttm)10.01 Insider Own0.13% Shs Outstand747.00M Perf Week-0.42%
Market Cap116.62B Forward P/E12.53 EPS next Y12.46 Insider Trans-0.30% Shs Float741.70M Perf Month5.22%
Income7.59B PEG2.25 EPS next Q2.79 Inst Own80.10% Short Float0.84% Perf Quarter-4.33%
Sales22.56B P/S5.17 EPS this Y35.20% Inst Trans0.10% Short Ratio1.50 Perf Half Y-3.18%
Book/sh41.20 P/B3.79 EPS next Y7.81% ROA10.10% Target Price181.73 Perf Year4.62%
Cash/sh50.84 P/C3.07 EPS next 5Y6.94% ROE25.80% 52W Range132.74 - 175.66 Perf YTD6.78%
Dividend4.60 P/FCF413.55 EPS past 5Y13.60% ROI12.50% 52W High-11.13% Beta1.15
Dividend %2.95% Quick Ratio4.10 Sales past 5Y7.60% Gross Margin81.50% 52W Low17.61% ATR2.91
Employees17900 Current Ratio4.30 Sales Q/Q1.50% Oper. Margin41.40% RSI (14)63.61 Volatility1.65% 1.56%
OptionableYes Debt/Eq1.15 EPS Q/Q9.80% Profit Margin33.60% Rel Volume0.63 Prev Close155.36
ShortableYes LT Debt/Eq0.99 EarningsFeb 02 AMC Payout37.50% Avg Volume4.16M Price156.12
Recom2.40 SMA203.51% SMA506.53% SMA200-0.43% Volume2,624,400 Change0.49%
Dec-20-16Downgrade Credit Suisse Outperform → Neutral
Dec-13-16Initiated Oppenheimer Outperform
Nov-08-16Initiated Mizuho Buy $164
Aug-26-16Initiated Gabelli & Co Hold
Jun-29-16Initiated Bernstein Mkt Perform
Feb-25-16Initiated Citigroup Neutral $165
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Jan-17-17 07:10AM  Better Buy: Amgen Inc. vs. Celgene Corporation at Motley Fool
Jan-13-17 04:32PM  Odds Are Against Regeneron, Sanofi In Amgen Patent Battle: Leerink
04:16PM  Trump's 'Disastrous' Pharma View Doesn't Rattle JPMorgan Drug Conference
03:52PM  [$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs at The Wall Street Journal
02:44PM  Supreme Court to hear a variety of business-related to ca...
02:33PM  Amgen Fight Over Copies of Biotech Drugs Gets High Court Review at Bloomberg
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at bizjournals.com
03:22PM  Investors in big pharma, biotech look to ride out Trump storm
01:23PM  Amgen, Inc. : AMGN-US: Dividend Analysis : November 16th, 2016 (record date) : By the numbers : January 12, 2017
11:56AM  [$$] Sanofi confident it can overturn Praluent patent ruling at Financial Times
09:35AM  Biotech Short Sellers Run for Cover
08:40AM  3 Cheap Value Stocks to Buy Today at Motley Fool
07:32AM  5 Things You Must Know Before the Market Opens Thursday
Jan-11-17 01:59PM  Trump's Comments Slam Drug Stocks at The Wall Street Journal
09:13AM  Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
08:24AM  Amgen: Phase III Data on Hyperparathyroidism Drug Published
Jan-10-17 04:12PM  Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis PR Newswire
03:23PM  Why Amgen's Stock Slumped in 2016 at Motley Fool
08:51AM  Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
Jan-09-17 08:48PM  Regeneron CEO says Amgen not putting patients first in patent dispute Reuters
06:21PM  Amgen Statement on January 9, 2017, U.S. District Court Decision PR Newswire
05:41PM  So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
02:59PM  Stocks Still Mixed, Medicals Lead Upside; Is Incyte The Next Amgen?
01:33PM  Bullish and Bearish Reversals in the Market
01:30PM  Morgan Stanley Cuts Regeneron Target On Praluent Patent Worries at Barrons.com
08:45AM  Amgen Launches Cancer Partnership With Immatics at Investopedia
08:15AM  Blog Coverage Amgen's Legal Victory Blocks Rivals Sanofi and Regeneron from Selling their Cholesterol Drug in the US Accesswire
08:14AM  5 Rocket Stocks for 2017 -- Amgen, eBay, More
06:12AM  AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreem
06:00AM  Amgen And DaVita Enter Into New Sourcing And Supply Agreement PR Newswire
04:00AM  Amgen and Immatics Enter Strategic Collaboration to Develop Novel Bispecific Cancer Immunotherapies PR Newswire
Jan-08-17 11:54PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
02:02PM  Why Biotech Titans Are Clashing Over Cholesterol at Motley Fool
Jan-07-17 10:47AM  Judges unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake at MarketWatch
Jan-06-17 08:09PM  Health Care, Banks Lead Game Strategy for Next Week: Cramer's 'Mad Money' Recap (Friday 1/6/17)
07:33PM  Sanofi Investors Count Cost of Praluent Ruling at The Wall Street Journal
06:41PM  Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today at Motley Fool
06:35PM  The Biggest Loser: Regeneron Sinks 5.8% at Barrons.com
06:16PM  Cramer's game plan: Banks will be in hog heaven next week at CNBC
05:00PM  Stocks to buy near Dow 20K: 4 trades
04:56PM  [$$] Amgen Patent Win Boosts Odds of a Stock Comeback at Barrons.com
04:40PM  Higher wages push stocks to records, but Dow misses 20,000
04:22PM  Could Sanofi Acquire BioMarin In Wake Of Amgen LDL Brouhaha?
04:13PM  Regeneron, Sanofi Hammered After Judge Bans Amgen-Rivaling LDL-Buster
03:52PM  [$$] Amgen Takes Stake in New Partner SiteOne at The Wall Street Journal
03:04PM  The C-Suite Braces for the Trump Era
02:12PM  Regeneron: Let's Make a Deal? at Barrons.com
02:10PM  Rally will fade away into second half: Analyst
01:59PM  Sanofi Counts Cost of Ruling That Blocks Its Cholesterol Drug at The Wall Street Journal
01:23PM  [$$] Regeneron Is Down, Not Out at The Wall Street Journal
12:57PM  Regeneron shares fall after judge blocks selling of cholesterol-lowering drug at CNBC
11:55AM  Fridays 6 Biopharma Movers That Cant Be Ignored
11:47AM  [$$] Regeneron shares tumble as US court blocks cholesterol drug at Financial Times
11:45AM  Amgen Set to Test Two Year Range Resistance (AMGN) at Investopedia
11:28AM  US STOCKS-S&P, Dow flat after jobs data; tech stocks lift Nasdaq
10:28AM  Could Amgen's Patent Victory Be Bad For Medicine? at Forbes
10:16AM  Regeneron, Sanofi Cholesterol Drug Gets Blocked at Investopedia
10:13AM  Amgen Shares Skyrocket on Surprise Patent Victory, Plus Jim Cramer's View
10:04AM  Gap soars on holiday sales cheer, Amgen jumps on patent win, Apple to open store in Samsung's home turf
09:56AM  US STOCKS-Wall St loses ground after mixed jobs data
09:40AM  Stock Open Lower After Jobs Report; Early Risers: Amgen, Ionis, Stemline
09:07AM  What Were Incytes Revenue Streams in 3Q16?
08:18AM  Regeneron Cholesterol-Lowering Drug Banned From U.S. Market at TheStreet
08:13AM  Amgen Establishes a Bottom and Signals It's Time to Buy
07:45AM  Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent
06:13AM  U.S. stock futures tread water ahead of jobs report at MarketWatch
05:53AM  Sanofi Investors Have Worst Day in Six Months
05:53AM  5 Things You Must Know Before the Market Opens Friday
05:50AM  Regeneron Cholesterol-Lowering Drug Banned From U.S. Market in Stunning Loss to Amgen in Patent Case
12:08AM  [$$] Judge Rules Against Sanofi and Regeneron in Patent Case at The Wall Street Journal
Jan-05-17 09:34PM  Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents PR Newswire
08:37PM  [$$] Judge Rules Against Sanofi and Regeneron in Patent Case at The Wall Street Journal
06:09PM  Amgen shares soar as judge blocks sales of Regeneron drug at MarketWatch
05:57PM  After-hours buzz: GPS, AMGN, SHAK & more at CNBC
05:52PM  Sanofi, Regeneron blocked from selling cholesterol drug
05:18PM  After Hours: Gap Gaps Up, Amgen Blocks Rival, Shake Shack Shakeup
04:51PM  Why the rising price of overdose antidotes?
04:46PM  Amgen Wins Ban on Sanofis Praluent Cholesterol Drug Sales at Bloomberg
12:36PM  Senate Dems, D.C. Watchdog Call for Investigation Into Trump HHS Pick Tom Price's Stock Portfolio
09:30AM  The Zacks Analyst Blog Highlights: Comcast, Amgen, General Mills, Target and Ford
08:52AM  This is how an investor turned around a once-venerable mutual fund at MarketWatch
Jan-04-17 04:09PM  Regeneron, Sanofi LDL-Buster At Risk After Judge Upholds Amgen Patents
04:00PM  Amgen To Present At The 35th Annual J.P. Morgan Healthcare Conference PR Newswire
02:30PM  Amgen Keeps Cholesterol Drug Patent Vs Regeneron at Investopedia
12:20PM  Stock Research Reports for Comcast, Amgen & General Mills
11:06AM  Regeneron: Who Cares If Amgen Won the Latest Patent Battle? at Barrons.com
09:21AM  These 3 Dividend Stocks Are Ridiculously Cheap at Motley Fool
07:21AM  Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
06:55AM  Kite Pharma (KITE) to Move Cancer Candidate into Phase I
05:21AM  Forget Buffett four unsung investment gurus are picking these eight stocks for 2017 at MarketWatch
Jan-03-17 10:36PM  Nikkei rises on weak yen but other Asian indexes mixed AP
02:44PM  Mean Reversion and the Bell Curve
Jan-02-17 11:54AM  Biotech Stocks: What to Watch in 2017 at Motley Fool
08:15AM  Amgen Plans Robust 2017 In Alzheimer's, Migraines, Oncology: CEO Exclusive
Jan-01-17 07:52AM  2 Healthcare Stocks With Better Dividends Than HCP, Inc. at Motley Fool
Dec-31-16 05:08PM  Amgen: Opportunity May Be Knocking
Dec-30-16 04:16PM  Gilead Sciences Valuation Compared to Its Peers
12:45PM  Which Top 5 Biotech Stocks In 2016 Are Slated For Triple-Digit Gains?
07:37AM  Cystic Fibrosis Strategy: Will It Boost Vertexs Future Revenues?
06:37AM  Merck (MRK) Does Well in 2016: Reasons for Outperformance
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Neulasta, a pegylated protein for the treatment of cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc; UCB; Novartis AG; Bayer HealthCare Pharmaceuticals Inc; Advaxis, Inc.; Dr. Reddy's Laboratories Ltd.; Biocartis Group NV; and Nuevolution AB. The company also has a strategic collaboration with Immatics Biotechnologies GmbH. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorSep 09Option Exercise71.645,000358,20021,171Sep 13 06:21 PM
Such Annette LouiseVP, Finance and CAOAug 02Sale174.593,000523,7587,183Aug 03 08:14 PM
Balachandran MadhavanEVP, OperationsMay 04Sale154.1230,0004,623,62455,996May 05 08:16 PM
BALTIMORE DAVIDDirectorApr 29Sale157.213,312520,68432,350May 03 07:12 PM
BALTIMORE DAVIDDirectorMar 30Option Exercise50.445,000252,20037,350Mar 31 06:01 PM
HERRINGER FRANK CDirectorMar 14Option Exercise50.445,000252,20030,608Mar 16 06:48 PM
COFFMAN VANCE DDirectorMar 09Option Exercise50.445,000252,20043,447Mar 10 06:55 PM
Bradway Robert AChairman, CEO and PresidentMar 02Option Exercise50.4484,0004,236,960447,102Mar 04 06:07 PM
Bradway Robert AChairman, CEO and PresidentMar 02Sale146.4820,0002,929,566383,102Mar 04 06:07 PM